NDA 019101 · Hikma
Fentanyl Citrate
Fentanyl Citrate · Injection
Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1984
Jul 11, 1984
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,750
243 Phase 3, 113 recruiting
FAERS reports
17,840
15,772 serious, 6,175 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF FENTANYL CITRATE INJECTION Addiction, Abuse, and Misuse Because the use of Fentanyl Citrate Injection exposes patients and other users to the risks of opioid addiction, abuse and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions ( 5.1 )] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of Fentanyl Citrate Injection, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Fentanyl Citrate Injection are essential [see Warnings and Precautions ( 5.2 )] . Risks From Concomitant Use With Benzodiazepines Or Other CNS...
What it is approved for
From the label in effect Oct 23, 2026.
Fentanyl Citrate Injection is indicated for: analgesic action of short duration during the anesthetic periods, premedication, induction and maintenance, and in the immediate postoperative period (recovery room) as the need arises. use as a narcotic analgesic supplement in general or regional anesthesia. administration with a neuroleptic as an anesthetic premedication, for the induction of anesthesia and as an adjunct in the maintenance of general and regional anesthesia. use as an anesthetic agent with oxygen in selected high-risk patients, such as those undergoing open heart surgery or certain complicated neurological or orthopedic procedures. Fentanyl Citrate Injection is indicated for: analgesic action of short duration during the anesthetic periods, premedication, induction and maintenance, and in the immediate postoperative period (recovery room) as the need arises. use as an opioid analgesic supplement in general or regional anesthesia. administration with a neuroleptic as an anesthetic premedication, for the induction of anesthesia and as an adjunct in the maintenance of general and regional anesthesia. use as an anesthetic agent with oxygen in selected high-risk patients, such as those undergoing open heart surgery or certain complicated neurological or orthopedic procedures.
Mechanism: Fentanyl Citrate Injection is an opioid agonist, whose principal actions of therapeutic value are analgesia and sedation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 11, 1984 Original approval
2 products under this application
- FENTANYL CITRATE · FENTANYL CITRATE EQ 0.025MG BASE/0.5ML · INJECTABLE, INJECTION · Discontinued
- FENTANYL CITRATE · FENTANYL CITRATE EQ 0.05MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Fentanyl" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Patient-controlled Intravenous Analgesia Combined With Different Opioid Receptors for Gastrointestinal SurgeryPivotal-lookingCompleted
Xijing HospitalAcademic, hospital or other
NCT05576675 · 4,342 participants · Start May 1, 2018 · Primary completion Mar 31, 2022
Drug: sufentanil + nalbuphine; Sufentanil and 1 more · For: Gastrointestinal Surgery
Sites: XIan, China
- Combined Use of Etomidate and Propofol in Painless Gastroscopy.Pivotal-lookingStatus unknown
Jiangsu Nhwa Pharmaceutical Co., Ltd.Industry
NCT01913054 · 2,450 participants (planned) · Start Aug 2013 · Primary completion Dec 2013
Drug: Fentanyl Injection; Etomidate Fat Emulsion Injection and 1 more · For: Safety of Gastroscopy
Sites: Beijing, China; Harbin, China; Wuhan, China · 6 sites in all
- Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer PainPivotal-lookingCompleted
Gachon University Gil Medical CenterAcademic, hospital or other
NCT00478101 · 2,006 participants · Start Feb 2006
Drug: oxycodone fentanyl · For: Advanced Solid Cancers
- Etomidate to Improve Outcome in Elderly PatientsPivotal-lookingCompleted
Zhihong LUAcademic, hospital or other
NCT02910206 · 1,917 participants · Start Aug 15, 2017 · Primary completion Nov 20, 2019
Drug: Etomidate; propofol and 2 more · For: Postoperative Complications
Sites: Xi'an, China
- Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)Pivotal-lookingRecruiting
Second Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT06452147 · 1,860 participants (planned) · Start Jun 19, 2024 · Primary completion Jul 30, 2028
Drug: Bupivacaine liposome; Regular local anesthetic and 1 more · For: Anesthesia; Hip Fractures; Dementia and 2 more
Sites: Dongyang, China; Hangzhou, China; Jinhua, China · 13 sites in all
- MAST Trial: Multi-modal Analgesic Strategies in TraumaPivotal-lookingCompleted
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03472469 · 1,561 participants · Start Apr 2, 2018 · Primary completion Jul 3, 2019
Drug: Acetaminophen IV/PO; Acetaminophen PO and 9 more · For: Nonspecific Pain Post Traumatic Injury
Sites: Houston, Texas
- Effect of Rematazolam Besylate, Propofol, and Sevoflurane Perioperative Sedation on Incidence of Emergence Agitation and Hemodynamics in Patients Undergoing Laparoscopic Abdominal SurgeryPivotal-lookingStatus unknown
Second Affiliated Hospital of Nanchang UniversityAcademic, hospital or other
NCT05624424 · 1,317 participants (planned) · Start Nov 15, 2022 · Primary completion Oct 31, 2023
Drug: Rematazolam Besylate; Propofol and 4 more · For: Emergence Agitation; Remimazolam Besylate; Perioperative Sedation and 2 more
Sites: Ganzhou, China; Jiujiang, China; Nanchang, China · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dependence3,935
- overdose2,456
- death2,065
- drug abuse1,737
- toxicity to various agents1,385
- ill-defined disorder1,288
- cardiac arrest918
- respiratory arrest737
- drug ineffective715
- drug hypersensitivity628
- nausea607
- pain574
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 72 |
| 2005 | 115 |
| 2006 | 235 |
| 2007 | 154 |
| 2008 | 261 |
| 2009 | 272 |
| 2010 | 1,148 |
| 2011 | 563 |
| 2012 | 696 |
| 2013 | 404 |
| 2014 | 429 |
| 2015 | 510 |
| 2016 | 595 |
| 2017 | 1,230 |
| 2018 | 1,319 |
| 2019 | 1,207 |
| 2020 | 1,031 |
| 2021 | 760 |
| 2022 | 834 |
| 2023 | 4,700 |
| 2024 | 599 |
| 2025 | 432 |
| 2026 | 272 |
Recalls
2 FDA enforcement reports for this application.
May 13, 2015 · Class III · Terminated
Failed Impurities/Degradation Specifications; 12 month stability testing (Expansion of RES #70548).
Feb 16, 2015 · Class III · Terminated
Failed Impurities/Degradation Specifications; 12 month stability testing.
Shortages
FDA's drug shortage list.
Current · updated Oct 14, 2026
Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25). Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.
Current · updated Oct 14, 2026
Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01). Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.
Current · updated Oct 14, 2026
Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25). Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.
Current · updated Oct 14, 2026
Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25). Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.
Current · updated Oct 14, 2026
Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25). Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Fentanyl Citrate (Fentanyl Citrate)
2024 spending
$886K
Beneficiaries
59
510 claims
Per beneficiary
$15,016
$13.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,457,692 |
| 2021 | $1,366,922 |
| 2022 | $1,233,015 |
| 2023 | $1,389,859 |
| 2024 | $885,973 |
Part D: Fentanyl Citrate* (Fentanyl Citrate/PF)
2024 spending
$53K
Beneficiaries
13,577
15,510 claims
Per beneficiary
$4
$1.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $17,226 |
| 2021 | $38,448 |
| 2022 | $65,012 |
| 2023 | $72,933 |
| 2024 | $53,186 |
Part B: Fentanyl Citrate (Fentanyl Citrate/PF) · HCPCS J3010
2024 spending
$181K
Beneficiaries
37,082
50,336 claims
Per beneficiary
$5
2024 ASP limit $0.93 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $400,962 |
| 2021 | $290,935 |
| 2022 | $274,248 |
| 2023 | $261,592 |
| 2024 | $180,781 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparison of Fentanyl, Remifentanil, Sufentanil and Alfentanil in Combination with Propofol for General Anesthesia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Sridharan K, Sivaramakrishnan G · Curr Clin Pharmacol 2019 · Comparative Study, Meta-Analysis
- Safety and effectiveness of adding fentanyl or sufentanil to spinal anesthesia: systematic review and meta-analysis of randomized controlled trials.
Fonseca NM, Guimarães GMN, Pontes JPJ, et al. · Braz J Anesthesiol 2023 · Meta-Analysis, Systematic Review
- Effect of Fentanyl for Preterm Infants on Mechanical Ventilation: A Systematic Review and Meta-Analysis.
Sudo Y, Seki-Nagasawa J, Kajikawa D, et al. · Neonatology 2023 · Meta-Analysis, Systematic Review
- Efficacy and Safety of Intranasal Fentanyl in Pediatric Emergencies: A Systematic Review and Meta-analysis.
Alsabri M, Hafez AH, Singer E, et al. · Pediatr Emerg Care 2024 · Comparative Study, Meta-Analysis
- Intranasal Fentanyl for Intervention-Associated Breakthrough Pain After Cardiac Surgery.
Valtola A, Laakso M, Hakomäki H, et al. · Clin Pharmacokinet 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy of Intrathecal Fentanyl for Cesarean Delivery: A Systematic Review and Meta-analysis of Randomized Controlled Trials With Trial Sequential Analysis.
Uppal V, Retter S, Casey M, et al. · Anesth Analg 2020 · Meta-Analysis, Systematic Review
Sponsor: Hikma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.